FDA approval for cholesterol-lowering injections
A new injectible treatment for cholesterol has been approved by the FDA.
Genzyme and Isis Pharmaceuticals have received US Food and Drug Administration approval for a new drug application for Kynamrotm injections.
The mipomsersen sodium treatment, administered 200mg weekly in a subcutaneous fashion, has been approved as an additional treatment alongside lipid-lower medications to reduce low density lipoprotein-cholesterol (LDL-C), apoliprotein B and total cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).
The rare condition involves the body being unable to properly process and remove LDL cholesterol from the blood, meaning that levels of so-called 'bad' cholesterol can rise significantly and result in cardiac arrest or mortality before the age of 30.
As a result of the approval, Genzyme will pay Isis $25 million in order to launch Kynamro commercially.
Dr Stanley T Crooke, chairman and chief executive of Isis, said: "Kynamro is the first systemic antisense drug to reach the market and is the culmination of two decades of work to create a new more efficient drug technology platform.
"We look forward to continuing to work with Genzyme toward a successful commercial launch of Kynamro and global expansion into other markets."
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance